It activates profibrotic signaling and primes kidney fibroblasts via the transforming growth factor beta (TGFb) pathway.22 In several studies, FGF23 was linked to CKD progression, CV events, and all-cause mortality in CKD patients.23,24 We show that higher FGF23 was indeed associated with all outcomes after adjustment for demographic parameters, blood pressure, comorbidities, kidney function and medications. This evidence concerns the gene FGF23 and chronic kidney disease.